Review analyzes glucocorticoid use in severe community-acquired pneumonia, suggesting individualized benefits and risks.
Severe community-acquired pneumonia (sCAP) is a serious respiratory disease that often requires urgent and comprehensive treatment. The use of glucocorticoids for the treatment of sCAP has been a focus of discussion in the medical community because of their potential benefits and safety concerns. A literature review showed that the benefits of glucocorticoids in the treatment of sCAP may be related to factors such as oxygenation index, high CRP levels, shock, non-influenza, female gender, early application, and hydrocortisone. The application of glucocorticoids in the treatment of sCAP needs to be considered on an individual basis, weighing the potential benefits and risks, and monitoring and preventing possible side effects.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: